4568
DAIICHI SANKYO COMPANY,LIMITED
Related News
Timely Disclosures
Securities Reports
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
/PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of
第一三共株式会社(証券コード: 4568)が発表した2026年度第1四半期(Q1)決算および事業進捗について、詳細かつ包括的な分析を行います。本レポートでは、決算数値の背景にあ